Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo with a broad range of content covering the utility of optical genome mapping (OGM) for cell and gene therapy and cancer research, including scientific workshops and poster presentations from Bionano and researchers from across the genomics landscape.
AMP's annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics. The AMP conference will be held November 14-18, 2023, in Salt Lake City, Utah.
A corporate workshop session titled "Structural Variant Insights from Adult and Pediatric CNS Tumors: Powered by Optical Genome Mapping," will be hosted by Dr. Chaubey, and will include a presentation from Drs. Terraf, Kolhe, and Bornhorst on their research regarding the role of SVs in CNS tumors. The presenters will share data on OGM's performance in this research application as compared to traditional cytogenetic methods of analysis, including microarrays. The session will take place on Wednesday, November 15 at 12:00 PM MT in Room 250C.
A second corporate workshop session, titled "Revolutionizing Cytogenomics with Optical Genome Mapping in Hematological Malignancies," will begin with a brief overview of the OGM workflow by Dr. Hastie, followed by Drs. Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies. The session will conclude with Dr. Smith presenting an international working group initiative and proposed framework for standardized implementation of OGM across cytogenetic research labs. The session will take place on Wednesday, November 15 at 1:00 PM MT in Room 250C.
As part of a session titled "Case Studies in Hematopathology," Dr. Nwogbo will present findings from his research using OGM to detect significant variants in CD5 negative low-grade B-cell lymphoma. The session will be held Friday, November 17, from 7:30- 7:45 AM MT in Room 255BC, Second Level.
Bionano leadership team members will host an Innovation Spotlight session titled "Unlocking Easy, Fast and Scalable Workflows for Optical Genome Mapping," where speakers will discuss how the OGM workflow offers researchers a transformative technique for high-resolution, genome-wide, comprehensive analysis of structural variation across research in cancer and genetic disease and will highlight product advancements and innovations. The presentation will take place Friday, November 17, from 12:00-12:30 PM MT on Stage 1.
In addition, 19 posters featuring results from OGM applications in cytogenetic research will be presented at the conference. All posters will be on display in the Convention Center, Expo Hall, Lower Level for the duration of the conference. Odd numbered posters will be presented November 17, from 9:15-10:15 AM MT. Even numbered posters will be presented November 18, from 9:15-10:15 AM MT. Posters may also be viewed here.
Scientific presentations and poster sessions from Bionano and collaborators include:
Poster Number | Title | Author |
G009 | Improved Genomic Classification in Myeloid Neoplasia Using Optical Genome Mapping and Panel-Based NGS | Smith A. |
H005 | Evaluation and Comparison of Optical Genome Mapping (OGM) to Standard of Care (SOC) Testing for Hematologic Malignancies on Residual Flow Cytometry Samples in a Clinical Diagnostics Laboratory Setting | Sen S. |
H11 | Advancing Myeloid Cancer Diagnostics with the Integrated Workflow of NGS and NxClinical for Copy Number Analysis: Going beyond the FISH | Vashisht A., Kolhe R. |
H015 | Optical Genome Mapping for Genome-Wide Structural Variation Analysis in Hematologic Malignancies: Results of a Prospective Study and Impact on Diagnosis and Management | Wicks S., Sahoo T. |
H022 | Chromoanagenesis: A Common Mechanism That Leads to Highly Complex Karyotype and Extensive Clonal Heterogeneity in Hematological Malignancies | Wei Q. |
H023 | Applying Optical Genome Mapping (OGM) to Detect and Monitor Genomic Biomarkers in Hematologic Malignancies | Pang A., Kim T., Chitsazan A., Hastie A. |
H038 | Optical Genome Mapping Reveals Known and Novel Chromosome Structure Across a Range of Hematological Malignancies in a Clinical Setting | Sathyanarayana S. |
H051 | Utility, Impact, and Challenges of Integrating Optical Genome Mapping (OGM) Technology in Routine Investigations of Hematological Malignancies: Real-World Experience | Singh H., Kolhe R. |
I029 | Genome Integrity Assessment by Optical Genome Mapping for Research in Cell and Gene Therapy, Stem Cell, and Bioprocessing Applications | Eastbrook J. |
ST027 | Clinical Validation Study of a 505-Gene Panel for Variant Detection in Diverse Solid Tumor Types | Vashisht A. |
ST119 | Novel Genomic Structural Variations in Angiosarcomas | Phung T., Hastie A. |
ST143 | Comparative Analysis of Chromosomal Microarray (CMA) and 505-Gene Next-Generation Sequencing (NGS) Panel for Homologous Recombination Deficiency (HRD) Phenotype Assessment in Solid Tumors | Vashisht A., Kolhe R. |
ST147 | Clinical Validation of NxClinical for Investigating Copy Number Alterations (CNA) by Next-Generation Sequencing (NGS) in Solid Tumors: A Potential Game Changer | Gupta V., Kolhe R. |
TT026 | Assessment of Genomic Scars Using NxClinical 6.2 Results in the Identification of Homologous Recombination Deficient Tumors in a Pediatric Cancer Cohort | Lansdon L., Yoo B. |
TT028 | Assessment of Homologous Recombination DNA Repair Deficiency (HRD) Score Generation Using Copy Number Profiling Data from Targeted NGS Compared to Chromosomal Microarray | Kanagal- Shamanna R. |
TT057 | Homologous Recombination Deficiency (HRD) Phenotype Assessment Using Chromosomal Microarray (CMA) and 523-Gene Next-Generation Sequencing (NGS) Panel: A Comparative Analysis | Vashisht A., Kolhe R. |
TT058 | Evaluation of Hi-C Sequencing as a Novel Diagnostic Technology for Detecting Genomic and Chromosomal Structural Variants in Constitutional Disorders | Fang H., Liu Y. |
TT062 | Optical Genome Mapping as Next-Generation Cytogenomic Technique in Clinical Laboratory: A 1000 Sample Experience | Singh H., Kolhe R. |
TT070 | Exploring the Utility of NxClinical Software in Investigating Copy Number Alterations (CNAs) in Myeloid Cancer Potential on Next-Generation Sequencing (NGS): A Potential Game Changer | Vashisht A., Kolhe R. |
Session | Title | Presenter/s | Presented |
Corporate Workshop, Session 1 | Structural Variant Insights from Adult and Pediatric CNS Tumors: Powered by Optical Genome Mapping | Bornhorst M., Chaubey A., Kolhe R., Terraf P. | November 15, 2023 12:00-12:50 PM MT Room 250C |
Corporate Workshop, Session 2 | Revolutionizing Cytogenomics with Optical Genome Mapping in Hematological Malignancies | Crocker S., Ryall S., Dubuc A., Hastie A., Smith A. | November 15, 2023 1:00-1:50 PM MT Room 250C |
Case Study Presentation | Variant t(2; 11)/IGK::CCND1 Rearrangement Detected by Optical Genome Mapping in a CD5 Negative Low-Grade B-cell Lymphoma | Nwogbo O. | November 17, 2023 7:30-7:45 AM MT Room 255 BC, Second Level |
Innovation Spotlight | Unlocking Easy, Fast, and Scalable Workflows for Optical Genome Mapping | Oldakowski M., Rose, K., Jiandani, D., Saul D. | November 17, 2023 12:00-12:30 PM MT Stage 1 |
"We are thrilled to see a record number of presentations featuring OGM at AMP this year," stated Erik Holmlin, PhD, president and chief executive officer of Bionano. "Our customers continue to push forward cutting-edge applications in areas including hematologic malignancy, cell and gene therapy and solid tumor research, and we look forward to the authors sharing their research with the AMP community."
More details on the conference can be found here.
Posted In: BNGO